Long-term prognosis after reperfusion therapy with emergency coronary angioplasty for acute myocardial infarction]

The influence of emergency coronary angioplasty (PTCA) for acute myocardial infarction on long-term survival was investigated. We followed 141 patients treated with emergency PTCA and 202 patients treated with thrombolytic therapy alone for a median of 1,157 days and a median of 2,133 days, respectively. All were initially completely occluded at the infarct-related coronary artery (IRCA). Actuarial survival curves were compared and independent predictors of late cardiac death were determined using Cox's proportional hazard model between overall patients and patients whose IRCA was at the proximal site of the left anterior descending artery (LAD). 1. Actuarial survival curves were similar in 2 groups. 2. Independent predictors of late cardiac death in overall follow-up patients were advanced age over 65 years (p < 0.03), a history of previous myocardial infarction (p < 0.03), severer stage of the Killip class on admission (p < 0.003), and the infarct-related proximal LAD (p < 0.01). 3. Among patients with the proximal LAD, the actuarial survival curve was better in those treated with emergency PTCA than in those treated with thrombolytic therapy alone (p < 0.01). 4. Among patients with the proximal LAD, independent predictors of late cardiac death were advanced age over 65 years (p < 0.03), treatment with thrombolytic therapy alone (p < 0.03), left ventricular ejection fraction < or = 40% (p < 0.06), and occluded IRCA on predischarge angiograms (p < 0.08). Among patients with the occluded proximal LAD, those treated with emergency PTCA showed better long-term survival rate than did patients with thrombolytic therapy alone, and this may be explained by higher successful reperfusion rates in the former than in the latter.     

稳妥开展急性心肌梗塞的经皮冠状动脉腔内成形术

稳妥开展急性心肌梗塞的经皮冠状动脉腔内成形术高润霖８０年代以来，急性心肌梗塞（ＡＭＩ）的治疗进入了再灌注治疗的年代，其中静脉溶栓治疗应用最为广泛。现已证明，溶栓治疗使冠状动脉再通，可明显改善ＡＭＩ近期及长期预后。据国家“八五”攻关课题研究组的报道，应...     

急性心肌梗死直接经皮腔内冠状动脉成形术治疗

临床上所说的急性心肌梗死(acutemyocardialinfarc tion,AMI)通常是指ST段抬高的心肌梗死(ST-seg mentelevationmyocardialinfarction,STEMI)。虽然有各种各样的药物和机械灌注治疗方法可供选择,包括溶栓和直接经皮腔内冠状动脉介入治疗(primarypercutaneouscoro naryintervent     

Percutaneous transluminal coronary angioplasty for acute myocardial infarction

Studies have suggested that intracoronary and intravenous thrombolysis and emergency PTCA result in decreased infarct size, improved left ventricular function, and decreased in-hospital mortality. Significant problems remain with all three treatment modalities. Thrombolysis is associated with significant bleeding, especially if acute catheterization also is performed. The intracoronary method of thrombolysis requires cardiac catheterization facilities and entails a significant delay in reperfusion. Lower rates of reperfusion initially were found with intravenous than intracoronary streptokinase, but the intravenous administration of t-PA has been associated with a reperfusion rate (75 per cent) similar to that of intracoronary streptokinase. Significant bleeding complications occur with t-PA just as with streptokinase. Furthermore, there are patients in whom thrombolysis is contraindicated because of the high risk of life-threatening hemorrhagic complications. Once thrombolysis is achieved, an underlying significant coronary artery lesion usually is present so that a significant risk of recurrent ischemia and/or reinfarction still exists. In controlled studies, the addition of cardiac catheterization and angioplasty after thrombolytic therapy is associated with a further increase in significant bleeding episodes. Also, in low-risk subgroups of patients randomized to emergency angioplasty versus elective angioplasty or noninvasive treatment after thrombolytic therapy, the complications of angioplasty may outweigh the benefits of further reduction in lesion severity. Potential problems of emergency angioplasty following thrombolytic therapy include: (1) hemorrhage into ischemic myocardium, which may have a deleterious effect on ultimate muscle recovery; (2) hemorrhage at the angioplasty site caused by thrombolytic therapy, with a resultant increased chance of occlusion of the vessel post-angioplasty, and (3) production of reperfusion arrhythmias and hypotension, predisposing to vessel reclosure and infarct extension. With primary angioplasty therapy, the reperfusion success rate is 85 to 90 per cent. This is higher than the approximately 75 per cent success rate with thrombolytic therapy alone. If angioplasty can be performed expeditiously, within 6 hours of the onset of ischemia, potential advantages of this technique include: (1) rapid reperfusion, possibly comparable to thrombolytic therapy alone; (2) higher success rate for reperfusion than thrombolytic therapy; (3) alleviation of underlying stenosis usually present after thrombolytic therapy alone; (4) avoidance of systemic thrombolysis, with a concomitant decrease in hemorrhagic risk; (5) possible avoidance of hemorrhagic infarction, which may have a deleterious effect on ultimate muscle recovery; and (6) applicability to patients in cardiogenic shock, who presently respond poorly to thrombolytic therapy alone. No large controlled randomized study exists comparing primary angioplasty with thr     

Complications of percutaneous transluminal coronary angioplasty in patients convalescing from acute myocardial infarction

Disagreement exists with regard to the role of percutaneous transluminal coronary angioplasty (PTCA) in patients convalescing from acute myocardial infarction (AMI). Routine PTCA within the tist few days after thrombolytic therapy offers no benefit beyond that resulting from thrombolysis.^1–3 Nevertheless, many physicians believe that even patients in stable condition are best served by diagnostic angiography and appropriate revascularization at some later point in their convalescence.⁴ However, there is evidence that the risk of death and major complications in such patients is greater than is true for PTCA performed outside the setting of AMI.^5,6 The Treatment of Post Thrombolytic-Stenoses Study Group encountered a mortality of 2.1% in stable patients treated electively with PTCA 4 to 14 days after AMI,⁷ a figure substantially greater than that in patients with no recent AMI.^5,6 Few data are available comparing the procedure-related morbidity and mortality associated with PTCA in contemporaneously treated patients with and without recent AMI. To provide insight into this issue, we compared results in those with AMI within 30 days of the PTCA with those with no such history.     

The efficacy and limitation of rescue coronary angioplasty for acute myocardial infarction]

Eighty one patients with acute transmural anterior myocardial infarction admitted to our hospital, from January, 1987 to February, 1991, were included in the present study. In 62 cases, reperfusion therapy was performed within 12 hours from the onset of chest pain. Forty nine patients underwent intracoronary thrombolysis, and in 16 patients (group RA) with failed thrombolysis (TIMI less than or equal to 1) percutaneous transluminal coronary angioplasty (PTCA) was performed as a "rescue" procedure. We studied the efficacy and limitation of rescue PTCA compared with direct PTCA (group DA, n = 13), intracoronary thrombolysis (group CT, n = 33) and conservative therapy without the above interventions (group N, n = 19). Initial reperfusion rate of intracoronary thrombolysis was 53% which was lower than group RA (88%) and group DA (100%) (p less than 0.05, p less than 0.01, respectively). Residual stenosis of infarct-related artery in the chronic phase (mean 28 +/- 7 days after initial intervention) in group CT was higher than group RA and group DA (p less than 0.01, p less than 0.01, respectively). LVEDVI in intervention groups (group CT, group RA, and group DA) were similar and significantly smaller than group N (p less than 0.05, p less than 0.05, and p less than 0.01, respectively). Ejection Fraction (EF) in intervention groups were significantly higher than group N. Regional wall motion of infarcted area in group CT and group DA were significantly better than group N (p less than 0.01, p less than 0.01, respectively). However, RWM in group RA was not significantly different compared with group N.(ABSTRACT TRUNCATED AT 250 WORDS)     

直接冠状动脉腔内成形术治疗急性心肌梗死

急性心肌梗死近年来大规模地推广应用静脉溶栓治疗,抢救了不少生命。直接经皮冠状动脉腔内成形术(PTCA)在急性心肌梗死的治疗上将又是一项有效的治疗措施。我科1995年8月～1998年4月,对46例急性心肌梗死病人作直接FTCA,取得满意临床效果。     

老年急性心肌梗死急诊介入治疗的临床效果

目的　探讨老年急性心肌梗死 (AMI)患者行急诊经皮冠状动脉介入治疗 (PCI)的临床效果。方法　 6 6例患者 ,年龄 6 0～ 88(6 8.3± 10 .2 )岁 ,其中 >75岁 18例 ;男 5 7例 ,女 9例。患者入院后经临床和心电图诊断 ,AMI诊断按 1979年 WHO提出的 AMI诊断标准。结果　 6 2例患者接受直接 PCI术 ,4例接受补救性 PCI。梗死相关血管 :前降支 2 4支 ,回旋支 11支 ,右冠状动脉 2 1支。有 6 3例患者的病变血管置入进口或国产支架 73枚 ,3例行经皮腔内冠状动脉成形术 (PTCA) ,残余狭窄 0～ 2 0 % ;开通后 6 0例患者血流达 TIMI 3级 ,5例患者 TIMI血流 级 ,1例患者血流 TIMI 0级。并发症与随访 :2例术后 4 8h内心源性休克死亡。对出院的 5 2例患者平均随访 (2 6 .1±13.3)月 (从 1个月至 78个月 ) ,再发急性心肌梗死 2例 ,心绞痛 4例 ,猝死 1例。结论　老年 AMI患者急诊介入性治疗可最大限度地恢复冠状动脉血流 ,手术成功率高 ,严重并发症少 ,是一种安全、有效的方法。尤其适应于高龄、有溶栓禁忌证或伴有心源性休克的患者。     

补救性经皮冠状动脉腔内成形术治疗急性心肌梗塞

目的探讨补救性经皮冠状动脉腔内成形术（ＰＴＣＡ）在治疗急性心肌梗塞（ＡＭＩ）中的作用。方法对溶栓治疗失败的３６例患者进行补救性ＰＴＣＡ治疗。患者心功能Ｋｉｌｐ分级：Ⅲ级和Ⅳ级４例，Ⅱ级和Ⅰ级３２例。冠状动脉造影显示梗塞相关动脉：前降支１７例，右冠状动脉１４例，回旋支４例，中间动脉１例。ＰＴＣＡ前ＴＩＭＩⅠ级和Ⅰ～Ⅱ级血流各２例，余３２例均为ＴＩＭＩ０级。３６例均进行ＰＴＣＡ治疗，其中１３例患者置入了支架。结果术中除３例失败外，３１例患者病变血管血流达到ＴＩＭＩⅢ级，２例ＴＩＭＩⅡⅢ级，残余狭窄≤５０％，成功率为９１．７％。院内并发症：１例在ＰＴＣＡ成功后当天因顽固性休克和心室纤颤死亡；１例于第３天死于心脏破裂，住院病死率为５．６％。１４例患者在术后１～２个月内复查冠状动脉造影，２例发生再狭窄。结论ＡＭＩ患者在溶栓治疗失败后，在有条件的医院可施行补救性ＰＴＣＡ治疗，成功率高，对改善患者的近期和远期预后可能有利     

Emergency percutaneous transluminal coronary angioplasty for acute myocardial infarction

Coronary angioplasty combined with thrombolytic therapy using urokinase (UK-PTCA) was attempted for acute myocardial infarction from September 1983 to December 1985, and without thrombolytic therapy (direct PTCA), thereafter. For UK-PTCA, the lesion was severely stenosed in 13, subtotally occluded in two and totally occluded in 21, and 29 lesions (81%) were successfully dilated. For direct PTCA, the lesion was stenosed in five, subtotally occluded in two and totally occluded in 14, and 19 lesions (90%) were dilated. Only one lesion in UK-PTCA had restenosis during hospitalization, but it was successfully redilated. Follow-up angiography was performed for 26 among 29 UK-PTCA cases and showed patency (diameter stenosis less than 50%) in 13, restenosis (less than 50%) in 12 and occlusion in one. Ten among 12 restenosed lesions were redilated and they were all patent at subsequent angiography. In 15 of 19 dilated lesions with direct PTCA, the lesion was patent in 10, and restenosed in five. Four of them were redilated and remained patent at subsequent angiography. Major complications occurred only in the UK-PTCA group before the judicious use of intra-aortic balloon pumping for hemodynamic instability. These included two deaths due to cardiogenic shock, one coronary dissection, and one sudden reocclusion, possibly due to thrombus formation. PTCA is applicable with or without thrombolytic therapy for acute myocardial infarction with high primary success rate and maintain coronary flow thereafter.     

Percutaneous transluminal coronary angioplasty in acute myocardial infarction

Percutaneous transluminal coronary angioplasty (PTCA) has, in general, been restricted to therapy for patients with angina pectoris. Thrombolytic therapy and guide wire recanalization have been used to recanalize coronary arteries in patients with evolving myocardial infarction. Recently we and others have examined the use of PTCA to recanalize the acutely occluded artery associated with the early evolving phase of myocardial infarction. PTCA was performed as definitive therapy in eight patients with acute myocardial infarction. Seven of these had totally occluded arteries to the region of infarct. The infarct-related artery was open within 20 minutes in each of these cases. PTCA recanalization resulted in evidence for reperfusion in each case. Residual stenoses either were not present or were minimal. The procedure was well tolerated. These preliminary results suggest that PTCA may be a reasonable alternative to intracoronary thrombolytic therapy in certain patients with acute evolving myocardial infarction.     

Multivessel coronary angioplasty early after acute myocardial infarction

Coronary angioplasty has been applied in patients with recent myocardial infarction, but results of angioplasty of multiple vessels early after myocardial infarction in patients with severe multivessel disease have not been reported. Coronary angioplasty of multiple vessels was performed in 105 patients 0 to 15 days (mean 5 +/- 4) after recent myocardial infarction. There were 77 men (73%) and 28 women (27%), with a mean age of 57 years. All patients had severe multivessel disease, 68% with two vessel and 32% with three vessel disease. Twenty-eight patients (27%) had successful thrombolysis before angioplasty and 70 (67%) had postinfarction angina. Mean left ventricular ejection fraction was 58 +/- 10% and was less than 45% in 13 patients (12%). Angioplasty was attempted in 319 lesions (mean 3 lesions per patient, range 2 to 9) and 252 vessels (mean 2.4 vessels per patient, range 2 to 4), with success in 302 lesions (95%) and 237 vessels (94%); angioplasty was done in two stages in 59 patients (56%). Clinical success was achieved in 102 patients (97%). Complications included myocardial infarction in six patients (5.7%) (one Q wave, five non-Q wave), urgent bypass surgery in two (1.9%) and death in one (0.9%); overall, seven patients (7%) had a major complication. All patients had a follow-up duration greater than 1 year (mean 31 months, range 12 to 73). Clinical recurrence developed in 24 patients (23%), of whom 21 had repeat angioplasty, 1 had bypass surgery and 2 were managed medically. Ten patients (9.8%) had a late infarction and 5 (4.9%) died of cardiac death during the follow-up period.(ABSTRACT TRUNCATED AT 250 WORDS)     

Percutaneous transluminal coronary angioplasty during acute myocardial infarction

Intravenous thrombolytic therapy with streptokinase in the setting of acute MI has been shown to be effective in improving left ventricular function, limiting infarct size, and improving early mortality. The benefit of this therapy is greatest when administered within 3 hours and is of minimal benefit when given more than 6 hours from symptom onset. Newer second generation thrombolytic agents such as intravenous r-TPA have been shown to be more effective at establishing patency of acutely thrombosed coronary arteries. TPA treatment produces patency rates similar to those observed with intracoronary administration of streptokinase (65 to 75 per cent). This agent will probably become standard therapy for patients with acute MI. Unfortunately, there are significant problems with systemic thrombolytic therapy. The potential for bleeding complications contraindicates the use of this therapy in patients with recent cerebrovascular events, recent surgery, or other possible bleeding problems. Acute angioplasty of the infarct-related artery has been shown to be effective in restoring blood flow in 85 per cent of patients with acute MI. Preliminary studies have suggested that this therapy, when administered within 4 hours from symptom onset, improves global and regional left ventricular function to a greater degree than intracoronary streptokinase. Patients receiving acute PTCA as a primary reperfusion modality have a lower incidence of post-infarction angina and provokable ischemia by exercise testing. If facilities and skilled personnel are available to perform PTCA within 4 hours from symptom onset, this therapy remains an alternative revascularization modality in patients with acute infarction and contraindications to systemic thrombolytic therapy. However, the benefit of PTCA with regard to reduction in mortality when used in this manner is unproven. PTCA can also be used as an adjunctive therapy administered at some time following systemic thrombolytic therapy. Performing PTCA acutely offers the potential to restore blood flow in 90 per cent of the patients that initially fail thrombolytic therapy. However, despite the use of PTCA in this subgroup, benefits with regard to improved ventricular function and decreased mortality have yet to be conclusively demonstrated. Performing acute PTCA following systemic thrombolytic therapy also incurs a high incidence of bleeding complications. If initial thrombolytic therapy reestablishes vessel patency, similar improvements in ventricular function can be expected even if PTCA is deferred until clinically indicated by evidence of recurrent ischemia.(ABSTRACT TRUNCATED AT 400 WORDS)     

Excimer laser coronary angioplasty in acute myocardial infarction

We evaluated the short-term results of percutaneous excimer laser angioplasty in acute myocardial infarction. Of the 18 patients studied, 2 were female and 16 male with a mean age of 56.6 +/- 12.1 years. Thrombolysis in myocardial infarction grades 0, 1, and 2 flow was observed in 10, 5, and 3 cases, respectively, prior to the procedure. The degree of stenosis was 97.9% +/- 5.1%. The lesion was crossed with a laser catheter in all cases, using a mean number of 808 +/- 384 laser pulses. Type C dissection developed in only 1 case (6%). Except for this case, distal flow was grade 3 in all the patients. Following the procedure, ST segment resolution exceeding 70% was achieved in 14 cases (78%) within the first 90 minutes. The success rate of laser ablation was 94% (17 patients). Stent implantation was performed in all the cases. In conclusion, laser angioplasty is an effective and reliable treatment for acute myocardial infarction.     

Percutaneous transluminal coronary angioplasty: Application for acute myocardial infarction

Seventy-eight of 1,000 consecutive PTCA procedures were performed in the setting of acute MI. Twenty-four of 26 patients with subtotal coronary occlusions underwent successful PTCA, including 9 patients with and 15 patients without previous intracoronary streptokinase infusions. Of 52 patients with total occlusions, PTCA was performed after reperfusion by streptokinase in 24 patients, after unsuccessful intracoronary streptokinase infusion in 6 patients and without previous thrombolytic therapy in 14 patients (27%). Six patients (7.7%) died. The immediate post-PTCA course was stable in 59 of 63 successfully dilated patients and 4 had coronary reocclusion. Late catheterization (mean 10 days) in 41 patients showed improved left ventricular function in most. At 6.5 months of follow-up, there were 9 restenoses that required PTCA, 1 reocclusion, 1 elective CABG and no deaths.